Protagonist Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
13analysts covering
Monitoring Framework
Key Performance Indicators
License and Collaboration Revenue Quarterly56.4M
Cash, Cash Equivalents, and Marketable Securities Quarterly620.3M
Icotyde (icotrokinra) Cumulative Prescriptions Quarterly11K
Watch Items
- FDA PDUFA Target Action Date for Rusfertide in Polycythemia VeraTrigger: FDA Approval DecisionAction: Monitor regulatory announcement and subsequent commercial launch milestones under Takeda collaboration.
- Icotyde (icotrokinra) Phase 3 Clinical Trial ProgressTrigger: Data readouts in psoriatic arthritis, ulcerative colitis, and Crohn's diseaseAction: Evaluate expansion of addressable market and potential milestone triggers.
- PN-881 Phase 1 Clinical Trial ResultsTrigger: Initial safety and tolerability data readoutAction: Assess early-stage pipeline progression for wholly-owned oral IL-17 antagonist.
Research as of 29 Jul 2026